Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus

Completed · Phase 2

Conditions studied: Esophageal Cancer

In brief

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have Barrett's esophagus.

Key facts

Study ID

NCT00005878

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Starts

2000-07-01

Expected to finish

2005-09-01

Last updated by the study team

2016-10-13

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Veterans Affairs Medical Center - Tucson — Tucson, Arizona, United States
• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital) — Hines, Illinois, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Herbert Irving Comprehensive Cancer Center — New York, New York, United States
• Ireland Cancer Center — Cleveland, Ohio, United States
• Veterans Affairs Medical Center - Portland — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.